东富龙科技集团股份有限公司（以下简称"公司"）第六届监事会第九次会 议于 2024 年 8 月 18 日以电话、书面方式通知各位监事，会议于 2024 年 8 月 29 日（星期四）在公司（上海市闵行区都会路 1509 号）305 会议室以现场会议方 式召开。本次监事会会议应出席的监事 3 名，实际出席会议的监事 3 名。本次会 议由监事会主席杨东生先生主持。公司董事会秘书列席本次会议。会议的召开符 合《公司法》及《公司章程》的有关规定。会议经认真审议，通过如下议案： 一、审议通过《公司 2024 年半年度报告及摘要》 监事会认为：董事会编制和审核公司 2024 年半年度报告全文及摘要的程序 符合法律、行政法规、中国证券监督管理委员会和深圳证券交易所的相关规定， 报告内容真实、准确、完整地反映了本公司实际的情况，不存在任何虚假记载、 误导性陈述或者重大遗漏。 证券代码：300171 证券简称：东富龙 公告编号：2024-036 东富龙科技集团股份有限公司 第六届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 赞成票，3 票，占出席会议 ...

Financial Performance - Revenue for the reporting period was RMB 2.29 billion, a decrease of 22.36% compared to the same period last year[15] - Net profit attributable to shareholders of the listed company was RMB 113.97 million, a decrease of 73.25% year-on-year[15] - Net cash flow from operating activities was RMB 191.97 million, a significant increase of 161.40% compared to the same period last year[15] - Basic earnings per share (EPS) were RMB 0.1498, a decrease of 73.44% year-on-year[15] - Weighted average return on equity (ROE) was 1.44%, down 4.13 percentage points from the same period last year[15] - Total assets at the end of the reporting period were RMB 12.91 billion, a slight increase of 0.11% compared to the end of the previous year[15] - The company achieved revenue of approximately 2.291 billion yuan in the first half of 2024, a decrease of 22.36% compared to the same period in 2023[39] - Net profit attributable to the parent company in the first half of 2024 was approximately 114 million yuan, a decrease of 73.25% year-on-year[39] - Revenue decreased by 22.36% to 2,290,913,300.80 yuan, primarily due to slower fixed asset investment by downstream customers[42] - Net cash flow from operating activities increased by 161.40% to 191,968,271.79 yuan, driven by higher cash receipts from sales and reduced payments for goods and taxes[42] - R&D investment decreased by 6.24% to 153,918,552.97 yuan, mainly due to stricter project management and reduced material costs[42] - The Formulation Division's revenue decreased by 20.36% to 1,259,013,745.93 yuan, with a gross margin of 31.41%[43] - The Bioprocess Division's revenue decreased by 32.73% to 538,395,099.18 yuan, with a gross margin of 29.86%[43] - Domestic revenue decreased by 24.11% to 1,798,061,366.65 yuan, while international revenue decreased by 15.21% to 492,851,934.15 yuan[43] - Investment income was 9,902,341.40 yuan, accounting for 6.98% of total profit, mainly from interest income and long-term equity investment gains[44] - Accounts receivable increased by 1.09% to 1,658,758,801.81 yuan, due to higher new receivables from revenue recognition compared to collections[46] - Inventory decreased by 1.10% to 3,472,349,676.25 yuan, driven by improved order delivery management and reduced obsolete stock[46] - Fixed assets increased by 1.07% to 955,500,284.08 yuan, mainly due to the transfer of the second phase of the pharmaceutical equipment manufacturing base project[46] - The company's total investment in the reporting period was RMB 246,737,130.73, a 2.59% increase compared to the same period last year[49] - The company's financial assets at fair value totaled RMB 819,794,548.08, with a fair value change gain of RMB 8,675,877.99 during the period[47] - Restricted monetary funds at the end of the reporting period amounted to RMB 34,155,364.53, primarily due to performance bonds, litigation frozen funds, and restricted overseas funds[48] - The company has cumulatively invested RMB 300,992.25 million in raised funds, with RMB 23,496.12 million invested during the reporting period[49] - The company invested RMB 5,597.90 million in the biopharmaceutical equipment industry trial center project using funds raised from specific object issuance[49] - The company invested RMB 12,124.29 million in the Jiangsu biopharmaceutical equipment industrialization base project using funds raised from specific object issuance[49] - The company invested RMB 5,773.93 million in the Zhejiang Dongfulong Biotechnology Co., Ltd. life science industrialization base project using funds raised from specific object issuance[50] - The aseptic freeze-drying pharmaceutical equipment system integration industrialization project has achieved a cumulative investment of RMB 16,037.8 million, with an investment progress of 54.18%[51] - The biopharmaceutical equipment industry trial center project has achieved a cumulative investment of RMB 12,990.55 million, with an investment progress of 24.51%[51] - The Jiangsu biopharmaceutical equipment industrialization base project has achieved a cumulative investment of RMB 28,916.33 million, with an investment progress of 46.64%[51] - Acquired Shanghai Dianfan Medical Technology Co., Ltd. and increased capital by 3,000 million RMB, holding 100% ownership[52] - Acquired Shanghai Ruipai Machinery Co., Ltd. and increased capital by 4,895 million RMB, holding 100% ownership[52] - Purchased a building in Yigu·Modern Business Park (Phase II) for 2,659.72 million RMB, holding 100% ownership[52] - Purchased a building in Wuhan Jiulong Bio-Industry Base Bio-Pharmaceutical Industrial Park Accelerator Phase II for 1,638.6 million RMB, holding 99.68% ownership[52] - Increased capital in Shanghai Dongfulong Intelligent Control Technology Co., Ltd. by 9,900 million RMB, holding 100% ownership[52] - Established Shanghai Dongfulong Medical Technology Industry Development Co., Ltd. with an investment of 50,000 million RMB, holding 100% ownership[52] - Acquired 40% equity of Shanghai Yufa Pharmaceutical Co., Ltd. for 3,600 million RMB, holding 100% ownership[52] - Increased capital in Shanghai Dongfulong Pharmaceutical Equipment Manufacturing Co., Ltd. by 37,000 million RMB, holding 100% ownership[52] - Total over-raised funds used amounted to 143,412.28 million RMB, with actual usage of 143,407.08 million RMB[57] - The pharmaceutical equipment container manufacturing base project (Phase I) did not meet expected profits due to relatively low gross margins in basic manufacturing[53] - Company used 36.1 million yuan of over-raised funds to increase its stake in Shanghai Chenghuan Light Industry Machinery Co., Ltd. to 51%[58] - Company used 22.5 million yuan of over-raised funds to acquire 15% equity in Shanghai Dongfulong Dehui Air Conditioning Equipment Co., Ltd., making it a wholly-owned subsidiary[58] - Company plans to use 370 million yuan of over-raised funds to invest in the construction of a biopharmaceutical system equipment industrialization project through its wholly-owned subsidiary Shanghai Dongfulong Pharmaceutical Equipment Manufacturing Co., Ltd.[58] - Company changed the implementation location of the "Aseptic Freeze-drying Pharmaceutical Equipment System Integration Industrialization Project" from No. 1509, Duhui Road, Minhang District, Shanghai to No. 139, Duhui Road, Minhang District, Shanghai[58] - Company used 17.51 million yuan of raised funds to replace self-raised funds previously invested in the pharmaceutical equipment container manufacturing base construction project (Phase I)[58] - Company used 173.81 million yuan of raised funds to replace self-raised funds previously invested in the 2022 specific object issuance project[58] - Company completed the replacement of 347.61 million yuan of raised funds for pre-paid issuance fees and self-raised funds invested in the 2022 specific object issuance project[58] - The pharmaceutical equipment container manufacturing base construction project (Phase I) had a net surplus of 45.93 million yuan after deducting unpaid quality assurance funds and balances[58] - The company saved part of the planned equipment purchase funds by using its own funds to purchase equipment in advance, resulting in a net surplus of 135.29 million yuan for the "Aseptic Freeze-Drying Pharmaceutical Integration Project"[59] - The "Aseptic Freeze-Drying Pharmaceutical Integration Project" had an actual investment of 160.71 million yuan, accounting for 54.29% of the committed investment amount[59] - The company transferred 165.31 million yuan of surplus funds from the "Aseptic Freeze-Drying Pharmaceutical Integration Project" to the over-raised funds account for management and use in main business development and related industrial investments[59] - The company used 26 million yuan to purchase a structured deposit from Bank of China with an expected annualized yield of 1.19%/3.2981%[60] - The company used 24 million yuan to purchase a structured deposit from Bank of China with an expected annualized yield of 1.20%/2.4324%[60] - The company used 26 million yuan to purchase a structured deposit from Bank of China with an expected annualized yield of 1.19%/2.4433%[60] - The company used 24 million yuan to purchase a structured deposit from Bank of China with an expected annualized yield of 1.20%/2.4218%[60] - The company used 26 million yuan to purchase a structured deposit from Bank of China with an expected annualized yield of 1.29%/2.4315%[60] - The company used 43 million yuan to purchase a structured deposit from Bank of China with an expected annualized yield of 1.30%/2.7304%[60] - The company used 47 million yuan to purchase a structured deposit from Bank of China with an expected annualized yield of 1.29%/2.7402%[60] - The company purchased a structured deposit of 20 million yuan from Ningbo Bank with an expected annualized return rate of 1.0000%-3.0000%, earning a profit of 299,178.08 yuan[61] - The company purchased another structured deposit of 30 million yuan from Ningbo Bank with an expected annualized return rate of 1.5%-2.8%[61] - The company transferred 4.375 million shares at a price of 35 million yuan, which was returned to the over-raised funds account[61] - The total amount of entrusted wealth management during the reporting period was 653.6561 million yuan, with 526.1561 million yuan not yet due[63] - Shanghai Hanou subsidiary achieved a net profit of 21.7776 million yuan, contributing significantly to the company's overall performance[67] - Dongfulong Medical subsidiary reported a net loss of 17.2898 million yuan, impacting the company's overall profitability[67] - The company faces risks from intense industry competition and is focusing on upgrading manufacturing and expanding international markets to mitigate these risks[69] - Economic cycle and market demand fluctuations pose risks, and the company is maintaining flexible production and supply chains to adapt to market changes[69] - The company is actively pursuing external mergers and acquisitions to accelerate growth in bioprocessing and food equipment engineering, which may increase management risks[69] - Internal management risks are heightened due to industry transformation, and the company is improving organizational models and management levels to meet market demands[69] - The company's actual controller, Zheng Xiaodong, increased his shareholding by 1,770,000 shares, accounting for 0.23% of the total shares, with a total investment of 30,025,652 yuan (excluding transaction fees)[74] - The company implemented a 2023 equity distribution plan, distributing 2.391867 yuan per 10 shares, totaling 182,306,270.32 yuan (including tax)[74] - The company completed a share repurchase of 4,980,001 shares, accounting for 0.6503% of the total shares, with a total repurchase amount of 63,943,727.13 yuan (excluding transaction fees)[74] - The company's 2023 annual general meeting had a 61.44% investor participation rate[76] - The company is focusing on internationalization, digitalization, and systemization, with continuous investment in R&D and technological cooperation in the biopharmaceutical industry[74] - The company is strengthening its management structure and internal control systems to improve operational standards[74] - The company is actively engaging with investors through hotlines and interactive platforms, and held an annual performance briefing after the 2023 annual report[75] - The company is addressing exchange rate risks by using financial tools, optimizing settlement methods, and enhancing the recruitment and training of financial professionals[70] - The company is mitigating investment impairment risks by strengthening post-investment management and strategic alignment with acquired companies[70] - The company is enhancing human resource management by building a learning organization and training platforms to support employee growth and value creation[70] - The company adjusted the number of incentive recipients for the 2021 restricted stock incentive plan from 383 to 368, with the total number of restricted shares remaining at 20 million[78] - The company granted 300,000 restricted shares to 19 incentive recipients at a price of 9.47 yuan per share on December 3, 2021, with 1.915 million reserved shares becoming invalid[78] - In the first vesting period of the 2021 restricted stock incentive plan, 7.078 million shares were vested by 352 recipients, with the shares becoming tradable on May 20, 2022[78] - In the first vesting period of the reserved portion of the 2021 restricted stock incentive plan, 108,000 shares were vested by 17 recipients, with the shares becoming tradable on January 20, 2023[79] - In the second vesting period of the 2021 restricted stock incentive plan, 5.1795 million shares were vested by 336 recipients, with the shares becoming tradable on May 29, 2023[80] - In the second vesting period of the reserved portion of the 2021 restricted stock incentive plan, 72,000 shares were vested by 15 recipients, with the shares becoming tradable on December 22, 2023[80] - In the third vesting period of the 2021 restricted stock incentive plan, 4.9875 million shares were vested by 311 recipients, with the shares becoming tradable on May 23, 2024[80] - The company has provided over 10,000 pharmaceutical equipment and systems to nearly 3,000 well-known pharmaceutical companies in more than 50 countries and regions globally[82] - The company has held investor meetings, conference calls, and roadshows, receiving recognition from the capital market and investor relations community[84] - Since its listing in 2011, the company has conducted annual equity distributions, providing stable returns to investors[84] - The company has established a comprehensive quality management system based on ISO9001, integrating ICHQ9 quality risk management and GMP standards to enhance customer satisfaction[86] - Products are designed for the pharmaceutical, food, and medical industries, utilizing 304 or 316L stainless steel materials and advanced SCADA systems for automation[86] - The company invests millions annually in environmental protection and energy conservation, including the use of solar power to reduce electricity consumption[88] - A robust EHS (Environment, Health, and Safety) system is in place, with regular environmental inspections and emergency response drills[87] - The company actively participates in social welfare activities, including educational support, poverty alleviation, and disaster relief efforts[88] - Employee benefits include comprehensive insurance, housing, meals, and annual health check-ups, with additional support for families in need[85] - The company adheres to strict labor laws, ensuring all employees are paid above the Shanghai minimum wage and receive annual performance-based bonuses[85] - Supplier relationships are managed through annual and strategic cooperation agreements, with a focus on quality and mutual development[86] - The company has implemented green manufacturing practices, such as using environmentally friendly refrigerants and energy-efficient compressors[86] - The company's commitment to sustainability includes regular updates to environmental policies and active participation in community environmental initiatives[87] - The company's total shares increased from 760,774,540 to 765,762,040 due to the third vesting period of the 2021 restricted stock incentive plan, with 4,987,500 shares issued[104] - The company's actual controller, Zheng Xiaodong, increased his holdings by 1,420,000 shares during the reporting period, with 1,065,000 shares locked under the 75% lock-up rule[105] - The company plans to repurchase shares worth between 50 million yuan and 100 million yuan, with an estimated repurchase of 2.14 million to 4.28 million shares, accounting for 0.28% to 0.56% of the total shares[105] - The company leased properties in Hangzhou, Shanghai, and Jinshan, including office spaces and land use rights, but none of these leases contributed more than 10% of the company's total profit[100] - The company's restricted shares increased by 1,656,750 shares, bringing the total restricted shares to 203,170,685, accounting for 26.53% of the total shares[104] - The company's unrestricted shares increased by 3,330,750 shares, bringing the total unrestricted shares to 562,591,355, accounting for 73.47% of the total shares[104] - The company repurchased 4,980,001 shares, accounting for 0.6503% of the total shares, with a total repurchase amount of RMB 63,943,727.13[106] - The repurchase price ceiling was adjusted from RMB 23.35 per share to RMB 23.11 per share due to the 2023 annual equity distribution[106] - The company's total shares increased from 760,774,540 to 765,762,040 after the listing of 4,987,500 restricted shares from the 2021 restricted stock incentive plan[106] - The total number of restricted shares held by executives increased from 201,513,935 to 203,170,685[108] - The largest shareholder, Zheng Xiaodong, holds 34.08% of the shares, with 195,719,256 shares under lock-up[109] - The second-largest shareholder, Zheng Keqing, holds 16.41% of the shares, with all 125,667,408 shares being freely tradable[109] - The top 10 shareholders include Shanghai Biopharmaceutical Industry Equity Investment Fund and SDIC Innovation Investment Management, each holding 3.17% of the shares[109] - The top 10 shareholders also include Shanghai Junhe Licheng Investment Management Center, holding 1.90% of the shares[109] - The top 10 shareholders include Gaoyi Asset Management Partnership, holding 1.88% of the shares[111] - The top 10 shareholders include Hong Kong Securities Clearing Company, holding 1.83% of the shares[111] - The company's monetary funds at the end of the

第六届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 东富龙科技集团股份有限公司（以下简称"公司"）第六届董事会第十一次 会议于 2024 年 8 月 18 日以电话、书面方式通知各位董事，会议于 2024 年 8 月 29 日（星期四）在公司（上海市闵行区都会路 1509 号）305 会议室以现场加通 讯的会议方式召开。本次董事会会议应出席董事 9 名，实际出席会议董事 9 名（独 立董事邵俊先生因公出差未亲自出席会议，授权委托独立董事张爱民先生代为出 席并行使表决权）。会议由董事长郑效东先生主持。公司监事及高级管理人员列 席本次会议。会议符合《公司法》及《公司章程》的有关规定。会议经认真审议， 通过如下议案： 证券代码：300171 证券简称：东富龙 公告编号：2024-035 东富龙科技集团股份有限公司 一、审议通过《2024 年半年度报告及摘要》 董事会认为，公司《2024 年半年度报告》全文及《2024 年半年度报告摘要》 符合法律、行政法规、中国证券监督管理委员会和深圳证券交易所的相关规定， 内容真实、准确、完整，不存在 ...

| | 浙江创新生物有限公 | 董事担任董事的 | 应收、合同资产、 | 145.87 | 9.98 | | 57.79 | 98.06 | 销售商品 | 经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 司 | 公司 | 合同负债 | | | | | | | | | | 康希诺生物股份公司 | 董事担任董事的 | 应收、合同资产、 | 31.60 | 5.87 | | 26.65 | 10.82 | 销售商品 | 经营性往来 | | | | 公司 | 合同负债 | | | | | | | | | | 上海雷昶科技有限公 | 董事担任董事的 | 应付、预付账款 | 134.34 | - | | 40.00 | 94.34 | 采购商品 | 经营性往来 | | | 司 | 公司 | | | | | | | | | | | 百剂博递医药科技 | 董事担任董事的 | 应收、合同资产、 | 13.80 | | | | 13.80 | 房屋出租 | 经营性往来 | | | （上海）有限公司 | 公司 | 合同负 ...

证券代码：300171 证券简称：东富龙 公告编号：2024-038 东富龙科技集团股份有限公司 关于公司 2024 年半年度计提资产减值准备及资产核销的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 一、本次计提资产减值准备 （一）情况概述 1、本次计提资产减值准备的原因 依照《企业会计准则》及东富龙科技集团股份有限公司（以下简称"公司"） 会计政策的相关规定，公司对合并范围内截止 2024 年半年度末的各类存货、应 收账款、合同资产、其他应收款、固定资产、在建工程、无形资产等资产进行全 面清查，对各类存货的可变现净值、应收款项回收的可能性、固定资产、长期股 权投资、在建工程、无形资产、商誉等资产的可变现性进行充分的评估和分析， 认为上述资产中部分资产存在一定的减值迹象，本着谨慎性原则，对可能发生资 产减值损失和信用减值损失的资产计提减值准备。 2、本次计提资产减值准备的资产范围和总金额 公司及下属子公司对 2024 年半年度末存在可能发生减值迹象的资产进行全 面清查和资产减值测试后，计提 2024 年半年度各项资产减值准备共计人民币 70,258, ...

东富龙科技集团股份有限公司 2024年半年度 募集资金存放与使用情况的专项报告 东富龙科技集团股份有限公司 2024 年半年度募集资金存放与实际使用情况的专项报告 | 项目 | 金额 | | --- | --- | | 募集资金净额 | 1,570,528,161.60 | | 减：以前年度已使用募集资金金额 | 1,730,322,891.92 | | 减：2024 年半年度使用募集资金金额 | - | | 加：累计募集资金利息收入扣除手续费净额 | 232,819,721.41 | | 其中：本年度募集资金利息收入减除手续费 | 2,038.63 | | 加：累计购买理财产品的收益 | 109,190,430.83 | | 其中：本年度购买理财产品的收益 | - | | 尚未使用的募集资金余额（注） | 182,215,421.92 | 注：截止 2024 年 6 月 30 日，尚未使用的募集资金余额 182,215,421.92 元， 全部存放于募集资金专户。截至 2024 年 6 月 30 日，超募资金（不含利息）已全 部使用完毕，尚未使用的募集资金余额均为累计的利息收入和理财收益。 根据中国证券监督 ...

证券代码：300171 证券简称：东富龙 公告编号：2024-034 东富龙科技集团股份有限公司 关于股份回购期限届满暨回购完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 东富龙科技集团股份有限公司（以下简称"公司"）于 2024 年 2 月 6 日召开 第六届董事会第八次（临时）会议，审议通过了《关于回购公司股份方案的议案》。 公司拟使用自有资金 5,000 万元（含）-10,000 万元（含）以集中竞价交易方式回 购公司部分已发行的人民币普通股（A 股）用于实施股权激励或员工持股计划， 若公司未能在股份回购完成后的 36 个月内用于上述用途，未使用部分将予以注 销。在本次回购价格上限 23.35 元/股（含）的条件下，按照本次回购资金总额上 限 10,000 万元（含）测算，预计可回购股份总数为 428.26 万股，约占公司当前 总股本的 0.56%；按照本次回购资金总额下限 5,000 万元（含）测算，预计可回 购股份总数为 214.14 万股，约占公司当前总股本的 0.28%。具体回购股份数量和 金额以回购期限届满或回购实施完成时实际回购 ...

证券代码：300171 证券简称：东富龙 公告编号：2024-033 东富龙科技集团股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 东富龙科技集团股份有限公司（以下简称"公司"）于 2024 年 2 月 6 日召开 第六届董事会第八次（临时）会议，审议通过了《关于回购公司股份方案的议案》。 公司拟使用自有资金 5,000 万元（含）-10,000 万元（含）以集中竞价交易方式回 购公司部分已发行的人民币普通股（A 股）用于实施股权激励或员工持股计划， 若公司未能在股份回购完成后的 36 个月内用于上述用途，未使用部分将予以注 销。在本次回购价格上限 23.35 元/股（含）的条件下，按照本次回购资金总额上 限 10,000 万元（含）测算，预计可回购股份总数为 428.26 万股，约占公司当前 总股本的 0.56%；按照本次回购资金总额下限 5,000 万元（含）测算，预计可回 购股份总数为 214.14 万股，约占公司当前总股本的 0.28%。具体回购股份数量和 金额以回购期限届满或回购实施完成时实际回购的股份数量 ...

证券代码：300171 证券简称：东富龙 公告编号：2024-032 东富龙科技集团股份有限公司 公司 2023 年年度权益分派实施方案为：以公司现有总股本 765,762,040 股剔 除已回购股份 3,569,701 股后的 762,192,339 股为基数，向全体股东每 10 股派 2.391867 元人民币现金（含税）。权益分派股权登记日为：2024 年 7 月 11 日， 除权除息日为：2024 年 7 月 12 日。具体内容详见公司于 2024 年 7 月 4 日披露 2023 年年度权益分派实施后调整回购价格上限的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 特别提示: 1、调整前回购股份价格上限：不超过 23.35 元/股（含）； 2、调整后回购股份价格上限：不超过 23.11 元/股（含）； 3、回购股份价格调整生效日期：2024 年 7 月 12 日（权益分派除权除息日）。 一、回购方案概述 东富龙科技集团股份有限公司（以下简称"公司"）于 2024 年 2 月 6 日召开 第六届董事会第八次（临时）会议，审议通过了《关于回购公司 ...

1、截至本公告披露日，东富龙科技集团股份有限公司（以下简称"公司"或 "本公司"）回购专用证券账户股份数量 3,569,701 股，不参与本次权益分派。公 司 2023 年年度权益分派方案为：以公司现有总股本剔除已回购股份 3,569,701 股 后的 762,192,339 股为基数，向全体股东每 10 股派 2.391867 元人民币现金。（含 税）。 2、本次权益分派实施后计算除权除息价格时，按总股本（含回购股份）折 算的每 10 股现金股利（含税）=现金分红总额/总股本×10=（总股本-回购股份） /10*2.391867 元/765,762,040 股×10=2.380716 元（保留六位小数，最后一位直接 截取，不四舍五入）。本次权益分派实施后的除权除息参考价格=权益分派股权 登记日收盘价-0.2380716 元/股。 证券代码：300171 证券简称：东富龙 公告编号：2024-031 东富龙科技集团股份有限公司 2023 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 特别提示： 公司 2023 年年度权益分派方案已获 ...